SGLT-2 inhibitors increase risk of amputation in T2DM

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1717卷 / 1期

关键词：

D O I：

10.1007/s40278-018-51082-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：12 / 12

相关论文

共 50 条

[1] Diabetes mellitus: Does SGLT-2 Inhibitors increase the Risk of Amputation?
Gallwitz, Baptist
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (06) : 366 - +
[2] Different safety profiles for SGLT-2 vs SGLT-1/2 inhibitors for T2DM
Reactions Weekly, 2022, 1900 (1) : 7 - 7
[3] SGLT-2 inhibitors and amputation: A real or an overestimated risk?
Xourgia, E.
Papazafiropoulou, A. K.
Melidonis, A.
ARCHIVES OF HELLENIC MEDICINE, 2019, 36 (03): : 320 - 325
[4] Which is better: SGLT-2 inhibitors compared to sitagliptin in older patients with heart failure and T2DM
Dahm, Johannes B.
AKTUELLE KARDIOLOGIE, 2023, 12 (05)
[5] SGLT2 inhibitors in people with and without T2DM
Khunti, Kamlesh
NATURE REVIEWS ENDOCRINOLOGY, 2021, 17 (02) : 75 - 76
[6] THE ROLE OF SGLT2 INHIBITORS IN THE MANAGEMENT OF T2DM
Jung, Chang Hee
JOURNAL OF HYPERTENSION, 2016, 34 : E186 - E186
[7] SGLT2 inhibitors in people with and without T2DM
Kamlesh Khunti
Nature Reviews Endocrinology, 2021, 17 : 75 - 76
[8] SGLT-2 inhibitors increase risk of bladder and renal cancer
Reactions Weekly, 2025, 2056 (1) : 12 - 12
[9] SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
Khouri, Charles
Cracowski, Jean-Luc
Roustit, Matthieu
DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1531 - 1534
[10] SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect?
Khouri, C.
Roustit, M.
Cracowski, J. L.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 80 - 80

← 1 2 3 4 5 →